Clinical Trial Update: T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a fully-human anti-CD19 CAR-T cell therapy for treating B-cell malignancies, with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell
• Lymphoma Non-hodgkin

Drugs mentioned

• CAR-T cell therapy targeting CD19 (fully-human anti-CD19 CAR)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lymphoma, B-Cell, Lymphoma, Non-hodgkins | Phase 1 | Status: COMPLETED | Results posted: 2021-05-04